A Phase 2 interventional study of Ziltivekimab in Chronic Kidney Diseases and Inflammation, sponsored by Novo Nordisk A/S. Completed at 49 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 9th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 11 more countries
Ages 18+
Novo Nordisk A/S · Sites in Korea, Republic of
Ages 19+
Novo Nordisk A/S · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–75
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 264 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 128 across the 18 interventional studies, 1,500 across the 11 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Renal Insufficiency, Chronic by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07808788Novo Nordisk A/SA Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function | 2027-07-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 mg and 30 mg subcutaneous monthly compared to placebo for six months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo
Biological: Ziltivekimab
Biological: Ziltivekimab
Biological: Ziltivekimab
Biological: Ziltivekimab
human IgG1k anti-human IL-6 monoclonal antibody
Also known as: COR-001
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels
Percent change from baseline in hs-CRP levels at week 13 are presented.
Time frame: Baseline (average of the hs-CRP value prior to randomization and day 1), week 13
Percent Change From Baseline in Serum Amyloid A (SAA)
Percent change from baseline in SAA at week 13 are presented.
Time frame: Baseline (average of the values at week -1 and day 1), week 13
Percent Change From Baseline in Fibrinogen
Percent change from baseline in fibrinogen at week 13 are presented.
Time frame: Baseline (day 1), week 13
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious AEs (TESAEs), Severe Hematologic AEs, Severe Non-hematologic AEs, and AEs Leading to Drug Discontinuation
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. TEAEs are defined as AEs that initiated or worsened on or after the date of first dose of study drug up to the end of safety-follow-up. A SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. TEAEs that met any of these criteria were considered severe hematologic AEs: grade 3 neutropenia, grade 3 anemia, grade 3 leukopenia, grade 3 lymphopenia, grade 3 eosinophilia, and grade 3 thrombocytopenia.
Time frame: From week 0 to week 32
Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Events
Bleeding events were classified using the TIMI bleeding classification as follows: 1) major: intracranial hemorrhage or a \>=5 g/dL decrease in the hemoglobin concentration or a \>=15 percent (%) absolute decrease in the hematocrit; 2) minor: (a) observed blood loss: \>=3 g/dL decrease in the hemoglobin concentration or \>=10% decrease in the hematocrit. (b) no observed blood loss: \>=4 g/dL decrease in the hemoglobin concentration or \>=12% decrease in the hematocrit; 3) minimal: any clinically overt sign of hemorrhage (including imaging) that was associated with a \< 3 g/dL decrease in the hemoglobin concentration or \<9% decrease in the hematocrit.
Time frame: From week 0 to week 32
Percentage of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESI)
An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. AESI included serious infections, malignancies, anaphylaxis occurring at any time, even if considered unrelated to the study drug, gastrointestinal perforations, hypersensitivity reaction during investigational product (IP) administration, neutrophils per cubic millimeter (500/mm\^3) (severe) or neutrophils \<1000/mm\^3 (severe) with evidence of concurrent infection, severe injection-related reactions, thrombocytopenia (platelet count \<50,000/mm\^3 (severe)) or platelet count \<75,000/mm\^3 (moderate) with evidence of concurrent TIMI major bleeding.
Time frame: From week 0 to week 32
Change in Systolic Blood Pressure (SBP)
Change from baseline in systolic blood pressure at week 32 are presented.
Time frame: Baseline (week 1), week 32
Change in Diastolic Blood Pressure (DBP)
Change from baseline in diastolic blood pressure at week 32 are presented.
Time frame: Baseline (week 1), week 32
Change in Respiratory Rate
Change from baseline in respiratory rate at week 32 are presented.
Time frame: Baseline (week 1), week 32
Change in Body Mass Index (BMI)
Change from baseline in BMI at week 24 are presented.
Time frame: Baseline (week 1), week 24
Change in Heart Rate
Change from baseline in heart rate at Week 32 are presented.
Time frame: Baseline (week 1), week 32
Change in Temperature
Change from baseline in temperature at week 32 are presented.
Time frame: Baseline (week 1), week 32
Change in Electrocardiogram (ECG)
The ECG was assessed by the investigator at baseline (week -1) and week 24 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 24 are presented.
Time frame: Baseline (week -1), Week 24
Change in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AAT) Levels
Change from baseline in ALP, ALT and AAT levels at week 32 are presented.
Time frame: Baseline (week 1), week 32
Change in Bicarbonate, Chloride, Potassium, Sodium
Change from baseline in bicarbonate, chloride, potassium, sodium at week 32 are presented.
Time frame: Baseline (week 1), week 32
Change in Direct Bilirubin, Bilirubin, Calcium, Creatinine, Glucose, Phosphate and Urea Nitrogen
Change from baseline in direct bilirubin, bilirubin, calcium, creatinine, glucose, phosphate and urea nitrogen at week 32 are presented.
Time frame: Baseline (week 1), week 32
Follicle Stimulating Hormone (FSH) Levels
FSH levels at baseline (week -1) are presented.
Time frame: Baseline (week -1)
Number of Participants With Anti-drug Antibodies (ADAs)
Participants who had at least 1 positive sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration were classified as positive for ADAs. In the instance that a participant had a positive sample at the baseline visit, the participant was considered positive only if the peak titer of the post-treatment sample was at least 2-fold higher (i.e., \>=2-fold) than the titer of the baseline sample. Number of participants positive for antibodies to Ziltivekimab are presented.
Time frame: From week 0 to week 32
The trial was conducted at 52 clinical sites in the United States.
| Milestone | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Started | 66 | 66 | 66 | 66 |
| Intent-to-treat analysis population | 66 | 66 | 66 | 66 |
| Safety analysis population | 65 | 65 | 66 | 65 |
| Treated | 65 | 65 | 66 | 65 |
| Completed | 60 | 57 | 60 | 59 |
| Not completed | 6 | 9 | 6 | 7 |
| Withdrew: Unclassified | 1 | 4 | 1 | 4 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 |
| Withdrew: Adverse event | 1 | 2 | 3 | 1 |
| Withdrew: Randomized but not treated | 1 | 1 | 0 | 1 |
Percent change from baseline in hs-CRP levels at week 13 are presented.
| Percent change | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels | -4.49 (-35.54 to 46.27) | -76.57 (-86.89 to -57.14) | -88.12 (-92.11 to -78.95) | -91.64 (-95.19 to -86.15) |
Percent change from baseline in SAA at week 13 are presented.
| Percent change | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Serum Amyloid A (SAA) | 1.82 (-18.42 to 50.98) | -40.24 (-61.54 to -12.38) | -49.80 (-63.90 to -31.54) | -42.45 (-68.91 to -13.48) |
Percent change from baseline in fibrinogen at week 13 are presented.
| Percent change | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Fibrinogen | -1.62 (-12.90 to 13.35) | -25.20 (-33.27 to -7.93) | -24.69 (-36.25 to -16.48) | -37.17 (-44.94 to -28.57) |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. TEAEs are defined as AEs that initiated or worsened on or after the date of first dose of study drug up to the end of safety-follow-up. A SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. TEAEs that met any of these criteria were considered severe hematologic AEs: grade 3 neutropenia, grade 3 anemia, grade 3 leukopenia, grade 3 lymphopenia, grade 3 eosinophilia, and grade 3 thrombocytopenia.
| Percentage of participants | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| TEAEs | 69.2 | 66.2 | 66.7 | 72.3 |
| TESAEs | 15.4 | 20.0 | 13.6 | 12.3 |
| Severe hematologic AEs | 1.5 | 0.0 | 1.5 | 0.0 |
| Severe non-hematologic AEs | 10.8 | 18.5 | 9.1 | 12.3 |
| AEs leading to study drug discontinuation | 4.6 | 6.2 | 7.6 | 4.6 |
Bleeding events were classified using the TIMI bleeding classification as follows: 1) major: intracranial hemorrhage or a \>=5 g/dL decrease in the hemoglobin concentration or a \>=15 percent (%) absolute decrease in the hematocrit; 2) minor: (a) observed blood loss: \>=3 g/dL decrease in the hemoglobin concentration or \>=10% decrease in the hematocrit. (b) no observed blood loss: \>=4 g/dL decrease in the hemoglobin concentration or \>=12% decrease in the hematocrit; 3) minimal: any clinically overt sign of hemorrhage (including imaging) that was associated with a \< 3 g/dL decrease in the hemoglobin concentration or \<9% decrease in the hematocrit.
| Percentage of participants | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Events | 0.0 | 0.0 | 0.0 | 0.0 |
An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. AESI included serious infections, malignancies, anaphylaxis occurring at any time, even if considered unrelated to the study drug, gastrointestinal perforations, hypersensitivity reaction during investigational product (IP) administration, neutrophils per cubic millimeter (500/mm\^3) (severe) or neutrophils \<1000/mm\^3 (severe) with evidence of concurrent infection, severe injection-related reactions, thrombocytopenia (platelet count \<50,000/mm\^3 (severe)) or platelet count \<75,000/mm\^3 (moderate) with evidence of concurrent TIMI major bleeding.
| Percentage of participants | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Serious infection | 4.6 | 10.8 | 4.5 | 3.1 |
| Malignancy | 1.5 | 0.0 | 1.5 | 1.5 |
| Anaphylaxis | 0.0 | 0.0 | 0.0 | 0.0 |
| Gastrointestinal perforations | 0.0 | 0.0 | 0.0 | 0.0 |
| Hypersensitivity reaction during IP administration | 0.0 | 0.0 | 0.0 | 0.0 |
| Neutropenia, severe | 0.0 | 0.0 | 0.0 | 0.0 |
| Neutropenia, severe with evidence of concurrent infection | 0.0 | 0.0 | 0.0 | 0.0 |
| Severe injection-related reaction | 0.0 | 0.0 | 0.0 | 0.0 |
| Thrombocytopenia, moderate with evidence of concurrent TIMI major bleeding | 0.0 | 0.0 | 0.0 | 0.0 |
| Thrombocytopenia, severe | 0.0 | 0.0 | 0.0 | 0.0 |
Change from baseline in systolic blood pressure at week 32 are presented.
| Millimeters of mercury (mmHg) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Change in Systolic Blood Pressure (SBP) | 4.8 ± 15.94 | 4.9 ± 16.31 | 0.6 ± 18.89 | 1.2 ± 14.71 |
Change from baseline in diastolic blood pressure at week 32 are presented.
| mmHg | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Change in Diastolic Blood Pressure (DBP) | 0.7 ± 10.33 | 2.9 ± 10.97 | 1.1 ± 11.17 | 3.1 ± 10.35 |
Change from baseline in respiratory rate at week 32 are presented.
| Breaths per minute (breaths/min) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Change in Respiratory Rate | 0.4 ± 2.24 | 0.2 ± 2.18 | -0.7 ± 2.36 | -0.5 ± 1.62 |
Change from baseline in BMI at week 24 are presented.
| Kilograms per square meter (kg/m^2) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Change in Body Mass Index (BMI) | 0.13 ± 1.102 | 0.51 ± 1.904 | 0.58 ± 1.664 | 0.40 ± 0.879 |
Change from baseline in heart rate at Week 32 are presented.
| Beats per minute (beats/min) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Change in Heart Rate | 2.8 ± 9.70 | 1.5 ± 10.18 | -0.6 ± 8.93 | 1.2 ± 11.56 |
Change from baseline in temperature at week 32 are presented.
| Degree Celsius (°C) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Change in Temperature | 0.03 ± 0.456 | -0.01 ± 0.430 | -1.13 ± 8.366 | -0.02 ± 0.615 |
The ECG was assessed by the investigator at baseline (week -1) and week 24 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 24 are presented.
| Participants | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Baseline (week-1) — Abnormal, clinically significant | 0 | 0 | 0 | 0 |
| Baseline (week-1) — Abnormal, not clinically significant | 44 | 38 | 40 | 46 |
| Baseline (week-1) — Indeterminate | 0 | 0 | 0 | 0 |
| Baseline (week-1) — Normal | 21 | 27 | 25 | 18 |
| Baseline (week-1) — Not evaluable | 0 | 0 | 0 | 0 |
| Baseline (week-1) — Unknown | 0 | 0 | 0 | 0 |
| Week 24 — Abnormal, clinically significant | 0 | 0 | 0 | 0 |
| Week 24 — Abnormal, not clinically significant | 36 | 32 | 35 | 34 |
| Week 24 — Indeterminate | 0 | 0 | 0 | 0 |
| Week 24 — Normal | 14 | 22 | 18 | 18 |
| Week 24 — Not evaluable | 0 | 0 | 0 | 0 |
| Week 24 — Unknown | 0 | 0 | 0 | 0 |
Change from baseline in ALP, ALT and AAT levels at week 32 are presented.
| Units per liter (U/L) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| ALP: Change from baseline to Week 32 | -1.9 ± 14.75 | -6.3 ± 18.28 | -9.6 ± 18.56 | -15.7 ± 13.94 |
| ALT: Change from baseline to Week 32 | 1.3 ± 5.53 | 2.6 ± 6.56 | 5.3 ± 11.76 | 7.2 ± 13.73 |
| AAT: Change from baseline to Week 32 | 0.6 ± 6.05 | 2.3 ± 4.65 | 3.3 ± 8.28 | 4.8 ± 9.15 |
Change from baseline in bicarbonate, chloride, potassium, sodium at week 32 are presented.
| millimoles per liter (mmol/L) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Bicarbonate: Change from baseline to Week 32 | -0.9 ± 2.60 | -0.3 ± 2.66 | -0.7 ± 2.96 | -1.2 ± 2.72 |
| Chloride: Change from baseline to Week 32 | 1.7 ± 3.86 | 0.0 ± 3.27 | 0.7 ± 2.95 | 0.9 ± 3.39 |
| Potassium: Change from baseline to Week 32 | 0.00 ± 0.445 | -0.28 ± 0.739 | -0.29 ± 0.570 | -0.16 ± 0.567 |
| Sodium: Change from baseline to Week 32 | 1.0 ± 2.92 | 0.0 ± 2.70 | 0.3 ± 2.44 | -0.1 ± 2.20 |
Change from baseline in direct bilirubin, bilirubin, calcium, creatinine, glucose, phosphate and urea nitrogen at week 32 are presented.
| milligrams per deciliter (mg/dL) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Direct Bilirubin: Change from baseline to Week 32 | -0.007 ± 0.0297 | 0.008 ± 0.0263 | 0.018 ± 0.0300 | 0.009 ± 0.0367 |
| Bilirubin: Change from baseline to Week 32 | -0.028 ± 0.1284 | 0.060 ± 0.1013 | 0.105 ± 0.1576 | 0.065 ± 0.1812 |
| Calcium: Change from baseline to Week 32 | -0.04 ± 0.494 | 0.09 ± 0.407 | 0.16 ± 0.524 | 0.11 ± 0.405 |
| Creatinine: Change from baseline to Week 32 | -0.041 ± 0.6114 | 0.216 ± 0.5291 | 0.054 ± 0.3404 | 0.141 ± 0.4618 |
| Glucose: Change from baseline to Week 32 | -15.1 ± 83.48 | 8.9 ± 80.50 | 9.2 ± 64.86 | 1.7 ± 48.43 |
| Phosphate: Change from baseline to Week 32 | -0.04 ± 0.778 | 0.04 ± 0.766 | 0.02 ± 0.620 | 0.21 ± 0.641 |
| Urea Nitrogen: Change from baseline to Week 32 | 0.4 ± 11.76 | 4.7 ± 12.15 | 1.6 ± 7.97 | 5.6 ± 13.89 |
FSH levels at baseline (week -1) are presented.
| International units per liter (IU/L) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Follicle Stimulating Hormone (FSH) Levels | 57.45 ± 20.496 | 72.70 ± 36.519 | 77.49 ± 33.827 | 58.79 ± 48.167 |
Participants who had at least 1 positive sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration were classified as positive for ADAs. In the instance that a participant had a positive sample at the baseline visit, the participant was considered positive only if the peak titer of the post-treatment sample was at least 2-fold higher (i.e., \>=2-fold) than the titer of the baseline sample. Number of participants positive for antibodies to Ziltivekimab are presented.
| Participants | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) | 0 | 4 | 5 | 7 |
Collected over From week 0 to week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/65 (1.5%) | 10/65 (15.4%) | 19/65 (29.2%) |
| Ziltivekimab 7.5 mg | 0/65 (0%) | 13/65 (20%) | 22/65 (33.8%) |
| Ziltivekimab 15 mg | 0/66 (0%) | 9/66 (13.6%) | 18/66 (27.3%) |
| Ziltivekimab 30 mg | 0/65 (0%) | 8/65 (12.3%) | 17/65 (26.2%) |
| Event | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/65 | 2/65 | 0/66 | 1/65 |
| Corona virus infectionInfections and infestations | 0/65 | 2/65 | 0/66 | 0/65 |
| Septic shockInfections and infestations | 0/65 | 2/65 | 0/66 | 1/65 |
| Abdominal painGastrointestinal disorders | 0/65 | 1/65 | 0/66 | 0/65 |
| Ankle fractureInjury, poisoning and procedural complications | 0/65 | 0/65 | 0/66 | 1/65 |
| Arteriovenous graft site infectionInfections and infestations | 0/65 | 1/65 | 0/66 | 0/65 |
| BradycardiaCardiac disorders | 0/65 | 0/65 | 0/66 | 1/65 |
| Cardiac arrestCardiac disorders | 1/65 | 0/65 | 0/66 | 0/65 |
| Cardiac failureCardiac disorders | 1/65 | 0/65 | 0/66 | 0/65 |
| Cardiac failure congestiveCardiac disorders | 1/65 | 0/65 | 1/66 | 1/65 |
| Event | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/65 | 2/65 | 1/66 | 3/65 |
| HypertensionVascular disorders | 2/65 | 5/65 | 6/66 | 0/65 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/65 | 1/65 | 3/66 | 2/65 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/65 | 4/65 | 2/66 | 1/65 |
| HypovolaemiaMetabolism and nutrition disorders | 2/65 | 4/65 | 0/66 | 0/65 |
| NasopharyngitisInfections and infestations | 1/65 | 4/65 | 3/66 | 3/65 |
| Oedema peripheralGeneral disorders | 2/65 | 4/65 | 1/66 | 4/65 |
| Urinary tract infectionInfections and infestations | 4/65 | 4/65 | 3/66 | 3/65 |
| DizzinessNervous system disorders | 1/65 | 3/65 | 4/66 | 3/65 |
Intent-to-treat (ITT) analysis population included all randomized participants.
| Age, Continuous(years) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 65.4 ± 10.81 | 67.2 ± 10.67 | 65.9 ± 9.42 | 67.1 ± 10.55 | 66.4 ± 10.35 |
| Sex: Female, Male(Participants) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|---|
| Female | 29 | 32 | 36 | 32 | 129 |
| Male | 37 | 34 | 30 | 34 | 135 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 25 | 12 | 15 | 19 | 71 |
| Not Hispanic or Latino | 41 | 54 | 51 | 46 | 192 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | Ziltivekimab 7.5 mg | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|---|
| Race — White | 50 | 48 | 49 | 52 | 199 |
| Race — Black or African American | 16 | 18 | 12 | 14 | 60 |
| Race — Asian | 0 | 0 | 3 | 0 | 3 |
| Race — Native Hawaiian or other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Race — Other | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Jun 2019 to primary completion in Jun 2020, 12 months.
Results were first posted in Aug 2023, 3 years 1 month after primary completion. A results delay was requested in May 2021.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 12 months is below that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziltivekimab
Renal Insufficiency, Chronic →